Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plasma exchange + Fecal microbiota transplant + Tenofovir
- Development stage
- Preclinical
- Lead developer
- Institute of Liver and Biliary Sciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous, Rectal, Oral
01
Overview
Plasma exchange + Fecal microbiota transplant + Tenofovir is a combination therapy regimen being investigated by the Institute of Liver and Biliary Sciences in India. This regimen combines a medical procedure (plasma exchange), a microbiome therapy (fecal microbiota transplant or FMT), and an antiviral drug (tenofovir). Plasma exchange works by removing harmful substances like toxins and inflammatory mediators from the blood. FMT aims to restore a healthy gut microbiome to reduce systemic inflammation. Tenofovir is an antiviral drug that specifically inhibits the replication of the hepatitis B virus (HBV). This combination is being studied for its efficacy in treating patients with acute-on-chronic liver failure (ACLF) resulting from HBV reactivation.
- Other names
- FMT + Plasma Exchange + TenofovirFMT + PLEX + Tenofovir
02
Targets
HBV Pol (Hepatitis B virus polymerase)POLG (Mitochondrial DNA polymerase gamma)
Beyond the preview
Go deeper on Plasma exchange + Fecal microbiota transplant + Tenofovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Plasma exchange + Fecal microbiota transplant + Tenofovir.